Company: MKLY
Filing Date: 2025-05-09
Form Type: DRS
Source: 0001213900-25-041164
Chunk: 29

Company: McKinley Acquisition Corp
Filing Date: 2025-05-09
Form: DRS
Chunk 29
---
465,000 private placement units (or 487,500 units if the underwriter’s over-allotment option is exercised in full)                |     |                      $4,650,000 (or $4,875,000 if the underwriter’s over-allotment option is exercised in full) |
|                       |     | Up to $125,000                                                                                                                    |     |             Repayment of loans made to us by our sponsor to cover offering-related and organizational expenses. |
|                       |     | Up to $1,500,000 in working capital loans may be convertible Private placement units at a price of $10.00 per unit                |     | Working capital loans to finance transaction costs in connection with an intended initial business combination. |
|                       |     | Reimbursement for any out-of-pocket expenses related to identifying, investigating and completing an initial business combination |     |          Services in connection with identifying, investigating and completing an initial business combination. |

____________ (1)Assumes no exercise of the over -allotmentoption and the full forfeiture of 853,448 shares that are subject to forfeiture by our initial shareholders depending on the extent to which the underwriter’s over -allotmentoption is exercised. (2)Our sponsor currently owns an aggregate of 6,543,103 Class B ordinary shares, which were purchased for an aggregate of $25,000 (or approximately $0.004 per share), up to 853,448 of which will be surrendered to us for no consideration after the closing of this offering depending on the extent to which the underwriter’s over -allotmentoption is exercised Because our sponsor acquired the founder shares at a nominal price, our public shareholders will incur immediate and substantial dilution upon the closing of this offering. See the section titled “ Risk Factors — Risks Relating to our Securities — The nominal purchase price paid by our sponsor for the founder shares may result in significant dilution to the implied value of your public shares upon the consummation of our initial business combination, and our sponsor is likely to make a substantial profit on its investment in us in the event we consummate an initial business combination, even if the business combination causes the trading price of our ordinary shares to materially decline.”

14

Pursuant to a letter agreement to be entered with us, each of our sponsor, directors and officers has agreed to restrictions on its ability to transfer, assign, or sell the founder shares and private placement units, as summarized in the table below.

| Subject